tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Sumant Kulkarni, 147 are a BUY (86.47%), 23 are a HOLD (13.53%).
Analyst Sumant Kulkarni, currently employed at CANACCORD, carries an average stock price target met ratio of 41.37% that have a potential upside of 33.58% achieved within 175 days.
Sumant Kulkarni’s has documented 336 price targets and ratings displayed on 24 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on NBIX, Neurocrine Biosciences at 28-Oct-2025.
Analyst best performing recommendations are on CARA (CARA THERAPEUTIC).
The best stock recommendation documented was for CARA (CARA THERAPEUTIC) at 6/13/2024. The price target of $10 was fulfilled within 4 days with a profit of $5.97 (37.38%) receiving and performance score of 93.46.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$29
$4.98 (20.73%)
$28
13 days ago
(05-Nov-2025)
0/11 (0%)
$7.35 (33.95%)
Buy
$32
$7.98 (33.22%)
$40
13 days ago
(05-Nov-2025)
0/3 (0%)
$10.35 (47.81%)
Buy
$33
$8.98 (37.39%)
$34
1 months 21 days ago
(28-Sep-2025)
8/13 (61.54%)
$11.68 (54.78%)
113
Buy
$39
$14.98 (62.36%)
$35
2 months 8 days ago
(10-Sep-2025)
7/12 (58.33%)
$14.8 (61.16%)
671
Buy
$39
$14.98 (62.36%)
$32
2 months 10 days ago
(08-Sep-2025)
1/5 (20%)
$14.16 (57.00%)
349
Which stock is Sumant Kulkarni is most bullish on?
Which stock is Sumant Kulkarni is most reserved on?
What Year was the first public recommendation made by Sumant Kulkarni?
